We have pioneered a new approach to partnering with pharmaceutical and biotech companies to help them develop effective new drugs and deliver them to patients in an accelerated manner.
This creative model, called Clinical Co-development, provides finance for late-stage therapeutic assets with the co-development company incurring all of the clinical and regulatory risk. The co-development company receives a pre-negotiated return once the drug is approved.
Abingworth has raised a $105 million fund dedicated to investing in Clinical Co-development that will co-invest with other Abingworth funds.
"Abingworth was the original lead investor in SFJ and has since made 5 additional investments in SFJ related companies. Working together to maximize the full potential growth and sustainability of SFJ, we have formed a true partnership with the Abingworth team."
Robert DeBenedetto, President and CEO of SFJ Pharmaceuticals"Abingworth are a very hands-on investor who bring their extensive experience in the life sciences sector to the board table. They have been a great support and used their connections to source exceptional individuals to join our growing company."
Allison Jeynes-Ellis, CEO of Avillion